Predictive and prognostic molecular markers for cancer medicine

Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes...

Full description

Bibliographic Details
Main Authors: Sunali Mehta, Andrew Shelling, Anita Muthukaruppan, Annette Lasham, Cherie Blenkiron, George Laking, Cristin Print
Format: Article
Language:English
Published: SAGE Publishing 2010-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834009360519
id doaj-462dc2877666490dbfec691ebd663024
record_format Article
spelling doaj-462dc2877666490dbfec691ebd6630242020-11-25T03:16:32ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83402010-03-01210.1177/1758834009360519Predictive and prognostic molecular markers for cancer medicineSunali MehtaAndrew ShellingAnita MuthukaruppanAnnette LashamCherie BlenkironGeorge LakingCristin PrintOver the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.https://doi.org/10.1177/1758834009360519
collection DOAJ
language English
format Article
sources DOAJ
author Sunali Mehta
Andrew Shelling
Anita Muthukaruppan
Annette Lasham
Cherie Blenkiron
George Laking
Cristin Print
spellingShingle Sunali Mehta
Andrew Shelling
Anita Muthukaruppan
Annette Lasham
Cherie Blenkiron
George Laking
Cristin Print
Predictive and prognostic molecular markers for cancer medicine
Therapeutic Advances in Medical Oncology
author_facet Sunali Mehta
Andrew Shelling
Anita Muthukaruppan
Annette Lasham
Cherie Blenkiron
George Laking
Cristin Print
author_sort Sunali Mehta
title Predictive and prognostic molecular markers for cancer medicine
title_short Predictive and prognostic molecular markers for cancer medicine
title_full Predictive and prognostic molecular markers for cancer medicine
title_fullStr Predictive and prognostic molecular markers for cancer medicine
title_full_unstemmed Predictive and prognostic molecular markers for cancer medicine
title_sort predictive and prognostic molecular markers for cancer medicine
publisher SAGE Publishing
series Therapeutic Advances in Medical Oncology
issn 1758-8340
publishDate 2010-03-01
description Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.
url https://doi.org/10.1177/1758834009360519
work_keys_str_mv AT sunalimehta predictiveandprognosticmolecularmarkersforcancermedicine
AT andrewshelling predictiveandprognosticmolecularmarkersforcancermedicine
AT anitamuthukaruppan predictiveandprognosticmolecularmarkersforcancermedicine
AT annettelasham predictiveandprognosticmolecularmarkersforcancermedicine
AT cherieblenkiron predictiveandprognosticmolecularmarkersforcancermedicine
AT georgelaking predictiveandprognosticmolecularmarkersforcancermedicine
AT cristinprint predictiveandprognosticmolecularmarkersforcancermedicine
_version_ 1724635561690398720